New stock news | Jiangxi Bio submitted three consecutive applications to the Hong Kong Stock Exchange

According to the Wisdom Financial APP, it was learned that on May 4th, the Hong Kong Stock Exchange disclosed that Jiangxi Bio Products Research Institute Co., Ltd. (referred to as Jiangxi Bio) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with China International Capital Corporation and CMB International Securities as joint sponsors. It is reported that Jiangxi Bio had previously submitted listing applications to the Hong Kong Stock Exchange on October 26, 2025, and April 11, 2025. The prospectus shows that Jiangxi Bio is the largest provider and exporter of human tetanus antitoxin (TAT) in China, and also a fully integrated antiserum platform provider. According to Frost & Sullivan data, the company is the largest provider of human TAT in China and globally, with market shares of 65.8% and 36.6% respectively based on sales in 2024. In 2025, the company's total sales of human TAT were 29.9 million units, with 13.5 million units sold in China and 16.4 million units exported to overseas markets.